China Isotope & Radiation (HKSE:01763) EBIT : HK$1,048 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation EBIT?

China Isotope & Radiation's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was HK$648 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,048 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. China Isotope & Radiation's annualized ROC % for the quarter that ended in Dec. 2023 was 9.94%. China Isotope & Radiation's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 26.71%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. China Isotope & Radiation's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 44.96%.

China Isotope & Radiation EBIT Historical Data

The historical data trend for China Isotope & Radiation's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Isotope & Radiation EBIT Chart

China Isotope & Radiation Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

837.42

748.17

1,026.69

1,067.72

1,048.47

China Isotope & Radiation Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial											665.25	386.15	699.85	400.20	648.28

Competitive Comparison of China Isotope & Radiation's EBIT

For the Medical Devices subindustry, China Isotope & Radiation's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Isotope & Radiation's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where China Isotope & Radiation's EV-to-EBIT falls into.

China Isotope & Radiation EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,048 Mil.

China Isotope & Radiation (HKSE:01763) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

China Isotope & Radiation's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	1010.5 * ( 1 - 13.88% )	/	( (9870.203	+	7647.692)	/ 2 )
=	870.2426	/	8758.9475
=	9.94 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	12903.126	-	653.447	-	( 2379.476	-	max(0, 4440.945	-	8141.448	+	2379.476	))
=	9870.203

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	14428.814	-	3638.641	-	( 3142.481	-	max(0, 4652.849	-	8962.937	+	3142.481	))
=	7647.692

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

China Isotope & Radiation's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1296.556	/	( ( (3224.069 + max(1340.15, 0))	+	(3938.886 + max(1206.484, 0)) )	/	2 )
=	1296.556	/	( ( 4564.219	+	5145.37 )	/	2 )
=	1296.556	/	4854.7945
=	26.71 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4048.616	+	914.053	+	694.099)	-	(653.447	+	0	+	3663.171)
=	1340.15

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4341.347	+	890.516	+	389.913)	-	(3638.641	+	0	+	776.651)
=	1206.484

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

China Isotope & Radiation's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	1048.474	/	2332.261
	=	44.96 %

China Isotope & Radiation EBIT Related Terms

Thank you for viewing the detailed overview of China Isotope & Radiation's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

China Isotope & Radiation (HKSE:01763) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089

Website

https://www.china-isotope.com

China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines